BlossomHill Therapeutics

Executive Summary

BlossomHill Therapeutics is a clinical-stage biotechnology company headquartered in San Diego, California, focused on designing and developing novel small molecule therapies for oncology and autoimmune diseases. Founded in 2018, the company leverages its team's proven track record in bringing FDA-approved precision medicines to market, combining human intelligence with advanced drug design to overcome limitations of existing treatments. While specific pipeline details are not publicly disclosed, BlossomHill's approach targets key unmet medical needs through innovative small molecule modalities, aiming to improve efficacy and safety profiles compared to current standards of care. The company operates in a competitive landscape but differentiates itself through creative medicinal chemistry and a deep understanding of disease biology. As a private entity, BlossomHill has not publicly disclosed funding rounds or valuation, but its clinical-stage status suggests ongoing development activities. The company's progress will depend on advancing its programs through preclinical and clinical milestones, with potential for partnerships or further financing to support its pipeline.

Upcoming Catalysts (preview)

• Q4 2026Initiation of Phase 1 clinical trial for lead oncology candidate40% success
• H1 2027Preclinical proof-of-concept data for autoimmune program50% success
• TBDStrategic partnership or licensing agreement for pipeline asset30% success